BACKGROUND: Glycodelin A levels in fluids of benign ovarian cysts, borderline tumours and ovarian cancer, as well as serum-levels of glycodelin A, were analysed in patients with benign and malignant ovarian tumours. The aim of the study was to investigate if the level of glycodelin A in body fluids of patients with malignant ovarian tumours could be a marker for the disease. Additionally, immunohistochemical investigations of glycodelin A expression in tissue of ovarian cancer were performed. MATERIALS AND METHODS: A total of 158 samples of fluids from benign ovarian cysts, borderline tumours and ovarian cancer were collected during surgery in the Department of Obstetrics and Gynaecology at the University of Rostock, Germany. Additionally, 69 samples of serum from patients with benign ovarian cysts and ovarian cancer on the day before surgery were collected. An ELISA for determination of glycodelin A was used. Immunohistochemical detection of glycodelin A expression was performed on ovarian cancer tissue from 38 patients. RESULTS: Malignant cystic fluids showed higher glycodelin A values (mean: 1814.4 ng/ml) compared to fluids of benign ovarian cysts (mean: 784.4 ng/ml). The results of glycodelin A determination were compared using the Mann- Whitney U-test for comparison of the means. There was a statistically significant difference between benign ovarian cysts and malignant ovarian cancer for the fluid (p <0.001). In addition, serum samples of malignant ovarian tumours also showed significantly higher glycodelin A values compared to serum levels of benign tumours (p<0.001). Immunohistochemical staining on ovarian cancer tissue showed a glycodelin A expression in 25-30% of the carcinoma cells. CONCLUSION: High levels of glycodelin A were found in cystic fluids of ovarian cancer. In addition, we also found higher levels of glycodelin A in the serum of patients with ovarian cancer compared to the serum of patients with benign ovarian cysts. Furthermore, ovarian cancer tissues showed intense staining with a glycodelin A antibody. Further investigations are necessary to show if glycodelin A quantification could help to diagnose ovarian cancer.
BACKGROUND:Glycodelin A levels in fluids of benign ovarian cysts, borderline tumours and ovarian cancer, as well as serum-levels of glycodelin A, were analysed in patients with benign and malignant ovarian tumours. The aim of the study was to investigate if the level of glycodelin A in body fluids of patients with malignant ovarian tumours could be a marker for the disease. Additionally, immunohistochemical investigations of glycodelin A expression in tissue of ovarian cancer were performed. MATERIALS AND METHODS: A total of 158 samples of fluids from benign ovarian cysts, borderline tumours and ovarian cancer were collected during surgery in the Department of Obstetrics and Gynaecology at the University of Rostock, Germany. Additionally, 69 samples of serum from patients with benign ovarian cysts and ovarian cancer on the day before surgery were collected. An ELISA for determination of glycodelin A was used. Immunohistochemical detection of glycodelin A expression was performed on ovarian cancer tissue from 38 patients. RESULTS: Malignant cystic fluids showed higher glycodelin A values (mean: 1814.4 ng/ml) compared to fluids of benign ovarian cysts (mean: 784.4 ng/ml). The results of glycodelin A determination were compared using the Mann- Whitney U-test for comparison of the means. There was a statistically significant difference between benign ovarian cysts and malignant ovarian cancer for the fluid (p <0.001). In addition, serum samples of malignant ovarian tumours also showed significantly higher glycodelin A values compared to serum levels of benign tumours (p<0.001). Immunohistochemical staining on ovarian cancer tissue showed a glycodelin A expression in 25-30% of the carcinoma cells. CONCLUSION: High levels of glycodelin A were found in cystic fluids of ovarian cancer. In addition, we also found higher levels of glycodelin A in the serum of patients with ovarian cancer compared to the serum of patients with benign ovarian cysts. Furthermore, ovarian cancer tissues showed intense staining with a glycodelin A antibody. Further investigations are necessary to show if glycodelin A quantification could help to diagnose ovarian cancer.
Authors: Marc A Schneider; Thomas Muley; Rebecca Weber; Sabine Wessels; Michael Thomas; Felix J F Herth; Nicolas C Kahn; Ralf Eberhardt; Hauke Winter; Gudula Heussel; Arne Warth; Christel Herold-Mende; Michael Meister Journal: Cancers (Basel) Date: 2018-12-04 Impact factor: 6.639
Authors: Harry J Whitwell; Jenny Worthington; Oleg Blyuss; Aleksandra Gentry-Maharaj; Andy Ryan; Richard Gunu; Jatinderpal Kalsi; Usha Menon; Ian Jacobs; Alexey Zaikin; John F Timms Journal: Br J Cancer Date: 2020-01-15 Impact factor: 7.640
Authors: Oleg Blyuss; Alex Gentry-Maharaj; Evangelia-Orania Fourkala; Andy Ryan; Alexey Zaikin; Usha Menon; Ian Jacobs; John F Timms Journal: Biomed Res Int Date: 2015-12-24 Impact factor: 3.411
Authors: Manuel A Vázquez; Inés P Mariño; Oleg Blyuss; Andy Ryan; Aleksandra Gentry-Maharaj; Jatinderpal Kalsi; Ranjit Manchanda; Ian Jacobs; Usha Menon; Alexey Zaikin Journal: Biomed Signal Process Control Date: 2018-09 Impact factor: 3.880
Authors: Florian Janke; Farastuk Bozorgmehr; Sabine Wrenger; Steffen Dietz; Claus P Heussel; Gudula Heussel; Carlos F Silva; Stephan Rheinheimer; Manuel Feisst; Michael Thomas; Heiko Golpon; Andreas Günther; Holger Sültmann; Thomas Muley; Sabina Janciauskiene; Michael Meister; Marc A Schneider Journal: Cancers (Basel) Date: 2020-04-12 Impact factor: 6.639